Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?

Bozkurt, Oktay; Karaca, Halıt; Hacıbekiroğlu, İlhan; Kaplan, Mehmet Ali; Düzköprü, Yakup; Uysal, Mükremın; Berk, Velı; İnanç, Mevlüde; Duran, Ayşe Ocak; Özaslan, Ersin; Uçar, Mahmut; Özkan, Metin

doi:10.1179/1973947815y.0000000039

Cited by 15 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A lot of predictive factors that were associated with worse ORR, shorter PFS or OS have been shown in previous retrospective studies (Table ) . Several studies have focused targeted molecules and their related factors in tumor tissues or serum, such as VEGFRs and tuberous sclerosis complex .…”

Section: Prognostic Factors For Mrcc Patients Treated With Targeted Tmentioning

confidence: 99%

“…Several studies showed that some AEs, such as hypertension or hand‐foot syndrome, were correlated with the efficacy of targeted agents . These AEs are defined as “on‐target AEs” and others are defined as “off‐target AEs.” On‐target AEs should be managed in order to continue targeted therapy, whereas management including stopping or changing agents is considered for off‐target AEs …”

Section: Prognostic Factors For Mrcc Patients Treated With Targeted Tmentioning

confidence: 99%

“…A lot of predictive factors that were associated with worse ORR, shorter PFS or OS have been shown in previous retrospective studies ( Table 2). [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] Several studies have focused targeted molecules and their related factors in tumor tissues or serum, such as VEGFRs and tuberous sclerosis complex. [18][19][20]30 Although genetic analysis or expression analysis for these molecules seem to be reasonable to identify prognostic markers in patients treated with targeted agents, it has not been so easy to assess this information during real clinical practice yet.…”

Section: Prognostic Factors For Mrcc Patients Treated With Targeted Tmentioning

confidence: 99%

“…On-target AEs should be managed in order to continue targeted therapy, whereas management including stopping or changing agents is considered for off-target AEs. 29 Previous studies showed that there were differences in prognosis depending on the site, size and the number of metastasis in patients with mRCC. 16,25 The prognosis of patients with liver or bone metastasis was worse compared with that of patients with lung or lymph node metastasis in both the era of cytokine therapy and targeted therapy.…”

Section: Prognostic Factors For Mrcc Patients Treated With Targeted Tmentioning

confidence: 99%

See 3 more Smart Citations

Current status of prognostic factors in patients with metastatic renal cell carcinoma

et al. 2019

View full text Add to dashboard Cite

In recent years, the induction of novel agents, including molecular‐targeted agents and immune checkpoint inhibitors, have dramatically changed therapeutic options and their outcomes for metastatic renal cell carcinoma. Several prognostic models based on the data of patients with metastatic renal cell carcinoma treated with targeted agents or cytokine therapy have been useful in real clinical practice. Serum or peripheral blood markers related to inflammatory response have been reported to be associated with their prognosis or therapeutic efficacy. In addition to them, investigation for novel predictive factors that represent the efficacy of agents, the risk of adverse events and the prognosis are required for the advance of therapeutic strategies. The present review discusses the conventional prognostic models and clinical factors, and recent advances of the identification of some of the most promising molecules as novel biomarkers for metastatic renal cell carcinoma.

show abstract

Section: Prognostic Factors For Mrcc Patients Treated With Targeted Tmentioning

confidence: 99%

Section: Prognostic Factors For Mrcc Patients Treated With Targeted Tmentioning

confidence: 99%

Section: Prognostic Factors For Mrcc Patients Treated With Targeted Tmentioning

confidence: 99%

Section: Prognostic Factors For Mrcc Patients Treated With Targeted Tmentioning

confidence: 99%

See 2 more Smart Citations

Current status of prognostic factors in patients with metastatic renal cell carcinoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…SUN-induced hypothyroidism has also been proposed as a possible predictive factor for the outcome of the cancer treatment, although the conclusions are still unclear [23][24][25][26][27]35,36]. A preliminary study of SUN treatment for mRCC suggested that hypothyroid patients had a significantly longer PFS than euthyroid patients [22].…”

Section: Hypothyroidism and Cancer's Outcomementioning

confidence: 99%

Role of Sunitinib-Induced Hypothyroidism in Oncological Patients

Baldelli¹

2017

EMIJ

View full text Add to dashboard Cite

Sunitinb (SUN) belongs to a new class of multi targeted tyrosine kinase inhibitors (TKIs) used in treatment of metastatic renal cell carcinoma, gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. Although generally well tolerated with favourable safety profile, SUN has distinct side effects that differ from the standard chemotherapy and require monitoring and management. Hypothyroidism is one of the most important adverse events induced by SUN. It is usually subclinical and rarely severe, with variable incidence. . The potential mechanisms involved in thyroid dysfunction are not fully understood. Generally, SUN-induced hypothyroidism does not require discontinuation of cancer therapy but only needs the thyroid replacement therapy. The occurrence of SUNinduced hypothyroidism appears with successful treatment in term of survival of oncological patients but more clinical investigations are necessary to validate this correlation.

show abstract

Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation

et al. 2018

View full text Add to dashboard Cite

Background/AimsHypothyroidism has been associated with hepatocellular carcinoma (HCC) incidence; however, the relationship between hypothyroidism and HCC patient outcomes is unclear. We investigated the impact of hypothyroidism on outcomes after liver transplantation for HCC.Materials and MethodsWe retrospectively studied HCC patients transplanted between January 2000 and December 2015. Hypothyroidism was defined as a thyroid‐stimulating hormone (TSH) level continuously greater than 5 mIU/L, a documented history of hypothyroidism, or treatment with thyroid hormone replacement therapy. Multivariate Cox regression was used to assess the impact of hypothyroidism on overall survival (OS) and recurrence‐free survival (RFS) adjusting for potential confounders. Subgroup analyses and interaction tests were conducted to compare the impact of hypothyroidism in different subgroups and assess for possible synergistic effects. Sensitivity analyses were performed among different cohorts to verify the stability of the results.ResultsA total of 343 HCC patients who underwent liver transplantation were included in the analysis. The primary analysis was conducted among 288 patients diagnosed with HCC prior to transplantation. Hypothyroidism was independently associated with worse OS and RFS, as was elevated TSH. The adjusted hazard ratio (AHR) of hypothyroidism was 2.45 (95% confidence interval [CI], 1.44‐4.18) for OS and 5.54 (2.36, 13.01) for RFS. The AHR of TSH for OS was 1.05 (1.02, 1.09) and 1.08 (1.03, 1.13) for RFS. No interaction was found among different subgroups categorized by etiology and comorbidity. The results were stable to sensitivity analyses.ConclusionHypothyroidism is associated with poorer overall and recurrence‐free survival of HCC patients receiving liver transplantation. These results require validation.

show abstract

Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?

Abstract: The occurrence of hypothyroidism during treatment in patients was significantly associated with longer PFS, OS and better ORR in the current study.

Cited by 15 publications

References 27 publications

Current status of prognostic factors in patients with metastatic renal cell carcinoma

Current status of prognostic factors in patients with metastatic renal cell carcinoma

Role of Sunitinib-Induced Hypothyroidism in Oncological Patients

Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation

Contact Info

Product

Resources

About